



(51) International Patent Classification:
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/GB2013/050624

(22) International Filing Date:
13 March 2013 (13.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/610,023 13 March 2012 (13.03.2012) US
61/610,012 13 March 2012 (13.03.2012) US

(71) Applicant: **RESPIVERT LIMITED** [GB/GB]; 50-100
Holmers Farm Way, High Wycombe, Buckinghamshire
HP12 4EG (GB).

(72) Inventors: **BROECKX, Rudy Laurent Maria**; c/o
Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340
Beerse (BE). **FILLIERS, Walter Ferdinand Maria**; c/o
Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340
Beerse (BE). **NIESTE, Patrick Hubert J**; c/o Janssen
Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse
(BE). **COPMANS, Alex Herman**; c/o Janssen Pharma-
ceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).
VANHOUTTE, Filip Marcel C; c/o Janssen Pharmaceut-
ica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **LEYS,**
Carina; c/o Janssen Pharmaceutica NV, Turnhoutseweg
30, B-2340 Beerse (BE).

(74) Agents: **TEUTEN, Andrew** et al.; Sagittarius IP, Three
Globeside, Fieldhouse Lane, Marlow, Buckinghamshire
SL7 1HZ (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE PI3 KINASE INHIBITORS

(57) Abstract: There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provided dry powder pharmaceutical compositions for inhalation containing such solid crystalline forms.

